Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iDose TR With iStent Infinite in Open-angle Glaucoma or Ocular Hypertension
NCT06066645Phase 4Recruiting
- Sponsor
- Glaukos Corporation
- Start
- Sep 2023
- Primary completion
- May 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Glaukos Corporation. Primary endpoint: Mean Diurnal Intraocular Pressure at 3 months. Started Sep 2023; status: recruiting.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT06066645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066645.